 |
|
| Blog results | Results 1 - 10 of about 22,289 for tumors + renal + small. (0.24 seconds) |
| Sorted by relevance Sort by date |
| 31 Dec 2000 Metastatic disease rarely occurs in patients with renal tumors less than 3 cm in diameter, data show. Latest articles from Renal and Urology... - http://www.renalandurologynews.com/ [ More results from Latest articles from Renal and Urology... ] |
| 14 Dec 2009 This ongoing, Phase 1/2, open-label, two-part study evaluates the safety and efficacy of neratinib in combination with weekly paclitaxel in patients with solid tumors and HER2 positive metastatic breast cancer (Poster #5081). ... Three patients discontinued therapy due to adverse events (renal failure, left ventricular ejection fraction reduction, and mouth ulceration). Phase 2 Safety Results of Neratinib Monotherapy in Patients with HER2 Positive Breast Cancer ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 9 Dec 2009 by CT Although the number of cases of this cancer is proportionally small, the tumor has a high avidity for bone and thus creates relatively large number of bone lesions. Patients are usually over 40, and the average age is around 55. ... Upekha - http://upekah.blogspot.com/ |
| 8 Dec 2009 by Dr. Simon E. Prince, FACP, FASN Surgeons at the University of Maryland School of Medicine in Baltimore have transplanted five kidneys from which they had removed small masses, three of which were cancerous. Four of the five patients have survived between nine months and 41 months so far without any evidence of recurring tumors. The fifth transplant patient died about a year after the operation because of a fall in an accident. “Transplanting a living donor kidney which has been affected by a renal mass ... Uremic Frost - http://www.uremicfrost.com/ - References |
| 3 Dec 2009 by "Renal Carincoid Guy" (BTW, IT WAS COMING AFTER ME ALSO, MY TUMORS HAS COVERED 60-70% OF MY LIVER! I WAS ALSO IN A LOT OF PAIN (THE LIVER HAS A "CAPSULE" COVERING IT AND IS FULL OF NERVES-- TOUCH IT, ENLARGED LIVER DUE TO TUMORS FOR EXAMPLE- AND ONE SEES ... My journey thru Neuroendocrine Carcinoma... - http://www.renalcarcinoid.com/ [ More results from My journey thru Neuroendocrine Carcinoma... ] |
| 23 Nov 2009 Sunitinib (SUTENT ®) has been approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced renal carcinoma patients and in gastrointestinal stromal tumor patients who are intolerant or progressed after imatinib ... Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r... [ More results from Clinical Trials Updates During the Last 7 Days ] |
| 20 Nov 2009 The researchers concluded: "Percutaneous RFA is a safe and effective treatment for small renal tumors in patients with high surgical risk or who refuse radical surgery." Hiraoka and colleagues published their study in International ... NewsRx Latest News for Professionals - http://www.newsrx.com/ |
| 6 Dec 2009 by admin Contact: Annette Whibley wizard.media@virgin.net Wiley-Blackwell Surgeons peform living donor transplants after removing small renal masses Surgeons who. ... Prior to the transplant, detailed discussions were carried out with each recipient and donor following the discovery of the renal masses in the donor kidney, so that they were both aware of the risks, including recurrence of the tumour. “The global increase in patients with end-stage renal disease highlights the ... BreakThrough Digest Medical News - http://www.breakthroughdigest.com/ - References |
| 15 Apr 2008 by van der Veldt, AAM, Meijerink, MR, van... Three patients underwent nephrectomy and tumors showed extensive necrotic areas next to small fields of vital tumor cells. Conclusions: Sunitinib can induce a significant reduction in volume of primary renal cell tumors. ... Clinical Cancer Research recent issues - http://clincancerres.aacrjournals.org/ [ More results from Clinical Cancer Research recent issues ] |
| 15 Dec 2009 In the solid tumor studies, 20 patients experienced prolonged stable disease and remained on study for four months or longer, five with NSCLC, one with small cell lung cancer, four with colorectal, two with bladder, two with gastrointestinal ... two with ovarian, one with breast, one with renal, one with parotid and one with an unknown primary tumor. Sapacitabine is part of Cyclacel's pipeline of small molecule drugs designed to target and stop uncontrolled cell division. ... GlobeNewswire: Pharmaceuticals News - http://www.globenewswire.com/newsroom/?kw=PHARMACEUTICALS [ More results from GlobeNewswire: Pharmaceuticals News ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
